Renovorx Inc (RNXT)

$0.90 -0.01 (-1.59%)
Market Cap 32.82M
Revenue (ttm) 40,000.00
Net Income (ttm) -8.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -22,025.00%
Debt to Equity Ratio 0.00
Volume 126,700
Avg Vol 306,214
Day's Range N/A - N/A
Shares Out 36.65M
Stochastic %K 39%
Beta 1.30
Analysts Strong Sell
Price Target $5.62

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 284 4433
Fax: 650 397 4433
Address:
2570 West El Camino Real, Suite 320, Mountain View, United States
WindVelocityW
WindVelocityW Dec. 25 at 10:00 AM
$RNXT Upside depends on translating ambition into measurable cadence, because growth without leverage now attracts skepticism. Measured progress can gradually rebuild conviction.
1 · Reply
Rnxtsavior
Rnxtsavior Dec. 24 at 7:17 PM
$RNXT For all the dummies that are going to believe this is tax loss selling.. and insiders are buying ... you are fools. This stock selling scam has been going on for 5 years. Following the sheeny man's script. THIS 100% WILL REVERSE SPLIT AND WIPE OUT ALL ORIGINAL INVESTORS.. NOT JUST THE DUMB RETAIL BUT ALL EARLY BIG INVESTORS/OFFERINGS. Then is will continue with maybe's and future dates while they continue this dump from India.
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 22 at 2:05 PM
$RNXT CEO purchased 5,000 shares at $0.90 for a total of $4,507. Bagai Shaun now owns 340,040 shares. https://ceo-buys.com
2 · Reply
TimRegan_WTR
TimRegan_WTR Dec. 19 at 4:29 PM
$RNXT
0 · Reply
research_WTR
research_WTR Dec. 19 at 4:07 PM
Read Robert Sassoon's recap from his recent podcast with Shaun R. Bagai, CEO of RenovoRx (Nasdaq: $RNXT). Those interested can listen to this podcast on all major platforms or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_Healt_12142025 $RNXT #RenovoRx #SmallCap #Podcast #Stocks #Investing #Healthcare
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 19 at 2:45 PM
$RNXT CEO purchased 5,000 shares at $0.85 for a total of $4,262. Bagai Shaun now owns 335,040 shares. https://ceo-buys.com
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 19 at 2:05 PM
$RNXT CEO purchased 5,000 shares at $0.85 for a total of $4,262. Bagai Shaun now owns 335,040 shares. https://ceo-buys.com
0 · Reply
iAccess_Alpha
iAccess_Alpha Dec. 19 at 1:48 PM
Did you miss $RNXT’s presentation? Replays are still available from iAccess Alpha’s Virtual Best Ideas Winter Conference. Watch here: https://www.webcaster5.com/Webcast/Page/3148/53256 #microcap #smallcap #investing
0 · Reply
TimRegan_WTR
TimRegan_WTR Dec. 18 at 8:41 PM
$RNXT
0 · Reply
research_WTR
research_WTR Dec. 18 at 8:03 PM
New Episode: WTR Healthcare Happenings – RenovoRx (Nasdaq: $RNXT) For full insights into RenovoRx’s platform, clinical strategy, and oncology market opportunity, listen to Robert Sassoon's full episode. Podcast Platforms: https://pod.link/1795488592 Website: https://www.watertowerresearch.com/media-detail/2914/Media $RNXT #Oncology #PancreaticCancer #DrugDelivery #Biotech #LifeSciences #WTRResearch #SmallCap #Stocks #Investing
0 · Reply
Latest News on RNXT
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

Dec 11, 2025, 8:30 AM EST - 15 days ago

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

Dec 9, 2025, 2:57 PM EST - 16 days ago

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Dec 1, 2025, 8:30 AM EST - 25 days ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

Nov 19, 2025, 8:30 AM EST - 5 weeks ago

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Nov 13, 2025, 4:05 PM EST - 6 weeks ago

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Nov 6, 2025, 8:30 AM EST - 7 weeks ago

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

Nov 4, 2025, 8:30 AM EST - 7 weeks ago

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Oct 27, 2025, 8:30 AM EDT - 2 months ago

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Oct 9, 2025, 8:30 AM EDT - 2 months ago

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Sep 25, 2025, 8:30 AM EDT - 3 months ago

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Sep 11, 2025, 8:30 AM EDT - 3 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 20, 2025, 8:30 AM EDT - 4 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 14, 2025, 4:05 PM EDT - 4 months ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Aug 6, 2025, 8:30 AM EDT - 5 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 28, 2025, 8:30 AM EDT - 5 months ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

Jul 14, 2025, 8:30 AM EDT - 5 months ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:07 PM EDT - 8 months ago

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 4:05 PM EDT - 8 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025, 8:30 AM EDT - 8 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025, 8:30 AM EDT - 8 months ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

May 1, 2025, 8:30 AM EDT - 8 months ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 29, 2025, 8:30 AM EDT - 8 months ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 16, 2025, 8:30 AM EDT - 9 months ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 4, 2025, 8:30 AM EDT - 9 months ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Apr 1, 2025, 8:30 AM EDT - 9 months ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 28, 2025, 8:00 AM EDT - 9 months ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 26, 2025, 8:00 AM EDT - 9 months ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 10 months ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Mar 19, 2025, 8:00 AM EDT - 10 months ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 26, 2025, 8:00 AM EST - 10 months ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 13, 2025, 8:00 AM EST - 11 months ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 11, 2025, 7:00 AM EST - 11 months ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 11 months ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Proposed Public Offering

Feb 6, 2025, 4:05 PM EST - 11 months ago

RenovoRx Announces Proposed Public Offering

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Feb 5, 2025, 2:14 AM EST - 11 months ago

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 27, 2025, 8:00 AM EST - 11 months ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Dec 30, 2024, 8:00 AM EST - 1 year ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Nov 20, 2024, 8:45 AM EST - 1 year ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Sep 25, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Sep 19, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Aug 27, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Aug 14, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

Jul 8, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Jun 26, 2024, 8:30 AM EDT - 1 year ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Jun 10, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

RenovoRx CEO Issues Update Letter to Shareholders

May 30, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Issues Update Letter to Shareholders

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

May 21, 2024, 9:00 AM EDT - 1 year ago

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

May 14, 2024, 9:00 AM EDT - 1 year ago

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

WindVelocityW
WindVelocityW Dec. 25 at 10:00 AM
$RNXT Upside depends on translating ambition into measurable cadence, because growth without leverage now attracts skepticism. Measured progress can gradually rebuild conviction.
1 · Reply
Rnxtsavior
Rnxtsavior Dec. 24 at 7:17 PM
$RNXT For all the dummies that are going to believe this is tax loss selling.. and insiders are buying ... you are fools. This stock selling scam has been going on for 5 years. Following the sheeny man's script. THIS 100% WILL REVERSE SPLIT AND WIPE OUT ALL ORIGINAL INVESTORS.. NOT JUST THE DUMB RETAIL BUT ALL EARLY BIG INVESTORS/OFFERINGS. Then is will continue with maybe's and future dates while they continue this dump from India.
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 22 at 2:05 PM
$RNXT CEO purchased 5,000 shares at $0.90 for a total of $4,507. Bagai Shaun now owns 340,040 shares. https://ceo-buys.com
2 · Reply
TimRegan_WTR
TimRegan_WTR Dec. 19 at 4:29 PM
$RNXT
0 · Reply
research_WTR
research_WTR Dec. 19 at 4:07 PM
Read Robert Sassoon's recap from his recent podcast with Shaun R. Bagai, CEO of RenovoRx (Nasdaq: $RNXT). Those interested can listen to this podcast on all major platforms or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_Healt_12142025 $RNXT #RenovoRx #SmallCap #Podcast #Stocks #Investing #Healthcare
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 19 at 2:45 PM
$RNXT CEO purchased 5,000 shares at $0.85 for a total of $4,262. Bagai Shaun now owns 335,040 shares. https://ceo-buys.com
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 19 at 2:05 PM
$RNXT CEO purchased 5,000 shares at $0.85 for a total of $4,262. Bagai Shaun now owns 335,040 shares. https://ceo-buys.com
0 · Reply
iAccess_Alpha
iAccess_Alpha Dec. 19 at 1:48 PM
Did you miss $RNXT’s presentation? Replays are still available from iAccess Alpha’s Virtual Best Ideas Winter Conference. Watch here: https://www.webcaster5.com/Webcast/Page/3148/53256 #microcap #smallcap #investing
0 · Reply
TimRegan_WTR
TimRegan_WTR Dec. 18 at 8:41 PM
$RNXT
0 · Reply
research_WTR
research_WTR Dec. 18 at 8:03 PM
New Episode: WTR Healthcare Happenings – RenovoRx (Nasdaq: $RNXT) For full insights into RenovoRx’s platform, clinical strategy, and oncology market opportunity, listen to Robert Sassoon's full episode. Podcast Platforms: https://pod.link/1795488592 Website: https://www.watertowerresearch.com/media-detail/2914/Media $RNXT #Oncology #PancreaticCancer #DrugDelivery #Biotech #LifeSciences #WTRResearch #SmallCap #Stocks #Investing
0 · Reply
MGeronimo
MGeronimo Dec. 17 at 9:05 PM
$RNXT added on 15k insider buy
0 · Reply
Wolfietrader
Wolfietrader Dec. 16 at 9:46 PM
$RNXT someone wanted out.
0 · Reply
Rnxtsavior
Rnxtsavior Dec. 16 at 8:52 PM
$RNXT Maybe some bad news after the close? Has that feel. BIG FAT REVERSE SPLIT?
0 · Reply
Rnxtsavior
Rnxtsavior Dec. 16 at 7:51 PM
$RNXT If results are good and sales are good... why is it .80's and dumping? You know why.... says it... you will feel better.
0 · Reply
Rnxtsavior
Rnxtsavior Dec. 16 at 7:49 PM
$RNXT Yikes... Sheeny man needs some Christmas money. He robbed you of your hard earned money and I'm the bad guy. Get what you can for your shares before you have to divide them by at least 20. Wiping out your investment.
0 · Reply
iAccess_Alpha
iAccess_Alpha Dec. 11 at 2:21 PM
$RNXT replay now available from iAccess Alpha’s Virtual Best Ideas Winter Conference. Replay here: https://www.webcaster5.com/Webcast/Page/3148/53256 #microcap #smallcap #investing
0 · Reply
Wolfietrader
Wolfietrader Dec. 11 at 2:05 PM
$RNXT news release just now.
1 · Reply
Mortz20
Mortz20 Dec. 10 at 4:23 AM
$RNXT anyone listen or view the presentation?
1 · Reply
iAccess_Alpha
iAccess_Alpha Dec. 9 at 1:42 PM
$RNXT will be presenting today at iAccess Alpha’s Virtual Best Ideas Winter Conference. December 9, 2025 | 12:30 PM ET Watch live via Stocktwits or access the webcast here: https://www.webcaster5.com/Webcast/Page/3148/53256 #microcap #smallcap #investing
0 · Reply
Wolfietrader
Wolfietrader Dec. 9 at 11:47 AM
$RNXT lots of news and exposure over the last couple of months. Would be nice to see some heavy buys and price appreciation, finally.
0 · Reply
iAccess_Alpha
iAccess_Alpha Dec. 8 at 2:26 PM
$RNXT will be presenting tomorrow at iAccess Alpha’s Virtual Best Ideas Winter Conference. December 9, 2025 | 12:30 PM ET Access the webcast here: https://www.webcaster5.com/Webcast/Page/3148/53256 #microcap #smallcap #investing
1 · Reply
Mortz20
Mortz20 Dec. 8 at 12:15 PM
$RNXT CMO bought 10000 more shares Dec 5th per SEC filing. Someone knows something…
1 · Reply